Shares of Vincerx, Inc. (NASDAQ:VINC – Get Rating) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.71.
A number of research analysts have recently weighed in on the company. Chardan Capital lowered their price target on Vincerx from $30.00 to $14.00 in a report on Wednesday, March 30th. HC Wainwright lifted their price objective on Vincerx from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, March 29th. B. Riley reduced their price objective on Vincerx from $26.00 to $12.00 in a research report on Tuesday, April 12th. SVB Leerink reduced their price objective on Vincerx from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, March 30th. Finally, Zacks Investment Research raised Vincerx from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Wednesday, April 20th.
Several hedge funds and other institutional investors have recently bought and sold shares of VINC. Deerfield Management Company L.P. Series C acquired a new position in shares of Vincerx during the 3rd quarter worth about $22,303,000. Rock Springs Capital Management LP acquired a new position in shares of Vincerx during the 3rd quarter worth about $12,941,000. Rubric Capital Management LP lifted its position in shares of Vincerx by 145.9% during the 3rd quarter. Rubric Capital Management LP now owns 1,312,406 shares of the company’s stock worth $21,222,000 after purchasing an additional 778,738 shares during the last quarter. Sphera Funds Management LTD. lifted its position in shares of Vincerx by 187.8% during the 3rd quarter. Sphera Funds Management LTD. now owns 654,572 shares of the company’s stock worth $10,584,000 after purchasing an additional 427,122 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Vincerx by 123.2% during the 3rd quarter. BlackRock Inc. now owns 728,091 shares of the company’s stock worth $11,773,000 after purchasing an additional 401,857 shares during the last quarter. 79.54% of the stock is owned by institutional investors and hedge funds.
Vincerx (NASDAQ:VINC – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.69. As a group, sell-side analysts forecast that Vincerx will post -3.14 EPS for the current fiscal year.
About Vincerx (Get Rating)
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.
- Get a free copy of the StockNews.com research report on Vincerx (VINC)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Vincerx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx and related companies with MarketBeat.com's FREE daily email newsletter.